Pharmacokinetics and pharmacodynamics: Interactions and adverse effects. Comparison with other echinocandins;Farmacocinética y farmacodinamia. Interacciones y efectos secundarios. Comparación con otras equinocandinas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 14, 2008, Pages 14-20

  Azanza, José Ramón ^a   Montejo, Miguel ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Drug interactions; Equinocandins; Pharmacodynamic; Pharmacokinetic

Indexed keywords

ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT;

BLOOD LEVEL; DIARRHEA; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; HEMATOCRIT; HUMAN; KIDNEY DISEASE; LEUKOCYTE; LEUKOPENIA; LIVER DISEASE; LIVER FAILURE; MONITORING; NAUSEA; NEUTROPENIA; OBESITY; PHLEBITIS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTE; THROMBOPHLEBITIS; VOMITING; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; DRUG MONITORING; ENZYMOLOGY; GASTROINTESTINAL DISEASE; HALF LIFE TIME; KIDNEY FAILURE; LIVER; METABOLISM; MYCOSIS; TISSUE DISTRIBUTION; TOXIC HEPATITIS;

AGED; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG MONITORING; ECHINOCANDINS; GASTROINTESTINAL DISEASES; HALF-LIFE; HEPATITIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LIVER; LIVER FAILURE; MYCOSES; OBESITY; TISSUE DISTRIBUTION;

EID: 69249231156     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76588-1     Document Type: Article

References (57)

1. A.H. Groll, D. Mickiene, R. Petraitiene, V. Petraitis, C.A. Lyman, and J.S. Bacher Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling Antimicrob Agents Chemother 45 2001 2845 2855 (Pubitemid 32906681)
2. T. Gumbo, G.L. Drusano, W. Liu, L. Ma, M.R. Deziel, and M.F. Drusano Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis Antimicrob Agents Chemother 50 2006 3695 3700 (Pubitemid 44684883)
3. G.M. Gauthier, T.M. Nork, R. Prince, and D. Andes Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis Clin Infect Dis 41 2005 e27 e28
4. J.A. Dowell, W. Knebel, T. Ludden, M. Stogniew, D. Krause, and T. Henkel Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal J Clin Pharmacol 44 2004 590 598 (Pubitemid 38668021)
5. J.A. Stone, X. Xu, G.A. Winchell, P.J. Deutsch, P.G. Pearson, and E.M. Migoya Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma Antimicrob Agents Chemother 48 2004 815 823 (Pubitemid 38280330)
6. J.A. Vazquez Anidulafungin: a new echinocandin with a novel profile Clin Therapeutics 27 2005 657 673
7. J.A. Stone, S.D. Holland, P.J. Wickersham, A. Sterrett, M. Schwartz, and C. Bonfiglio Single- and multiple-dose pharmacokinetics of caspofungin in healthy men Antimicrob Agents Chemother 46 2002 739 745 (Pubitemid 34157659)
8. S.K. Balani, X. Xu, B.H. Arison, M.V. Silva, A. Gries, F. DeLuna, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine Drug Metab Dispos 28 2000 1274
9. M. Stogniew, F. Pu, T. Henkel, and J. Dowell Anidulafungin biotransformation in human is by degradation not metabolism 13th European Congress Clinical Microbiology and Infectious Glasgow 2003 P1223
10. P. Sandhu, W. Lee, X. Xu, B.F. Leake, M. Yamazaki, and J.A. Stone Hepatic uptake of the novel antifungal agent caspofungin Drug Metab Dispos 33 2005 676 682 (Pubitemid 40593883)
11. J.A. Dowell, M. Stogniew, D. Krause, and B. Damle Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment J Clin Pharmacol 47 2007 461 470 (Pubitemid 46465954)
12. J.A. Stone, S. Holland, S. LI, P. Wickersham, P. Deutsch, G. Winchell, et al. Effect of hepatic insufficiency on the pharmacokinetics of Caspofungin 41th Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 A14 September and December
13. D. Thye, T. Kilfoil, R. White, and K.C. Lasseter Anidulafungin phamacokinetics in subjets with mild and moderate hepatic impairment 41th Interscience Conference on antimicrobial agents and chemotherapy Washington 2001 A34
14. D. Thye, T. Kilfoil, Kifoil., and T. Henkel Anidulafungin phamacokinetics in subjets with severe hepatic impairment 42th Interscience Conference on antimicrobial agents and chemotherapy San Diego 2002 A1392
15. J.A. Stone, C. Ballow, S.D. Holland, P.J. Deusch, W. Hauck, E. Pequignot, et al. Single dose caspofungin pharmacokinetics in healthy elderly subjets 40th Interscience Conference on antimicrobial agents and chemotherapy Washington 2000 853
16. T.J. Walsh, P.C. Adamson, N.L. Seibel, P.M. Flynn, M.N. Neely, and C. Schwartz Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents Antimicrob Agents Chemother 49 2005 4536 4545 (Pubitemid 41552583)
17. D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, C.E. Gonzalez, M.M. Roden, and R. Kilaru Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections Antimicrob Agents Chemother 50 2006 632 638 (Pubitemid 43190976)
18. T.H. Nguyen, T. Hoppe-Tichy, H.K. Geiss, A.C. Rastall, S. Swoboda, and J. Schmidt Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit J Antimicrob Chemother 60 2007 100 106 (Pubitemid 47073282)
19. C.M. Douglas Fungal beta(1,3)-D-glucan synthesis Med Mycol 39 Suppl 1 2001 55 66
20. U. Frank, M. Greiner, I. Engels, and F.D. Daschner Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes Eur J Clin Microbiol Infect Dis 23 2004 729 731 (Pubitemid 39304331)
21. R. Petraitiene, V. Petraitis, A.H. Groll, M. Candelario, T. Sein, and A. Bell Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits Antimicrob Agents Chemother 43 1999 2148 2155 (Pubitemid 29421192)
22. T. Gumbo Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies Curr Opin Infect Dis 20 2007 587 591 (Pubitemid 350059518)
23. U. Theuretzbacher Pharmacokinetics/pharmacodynamics of echinocandins Eur J Clin Microbiol Infect Dis 23 2004 805 812 (Pubitemid 40378995)
24. D. Andes, D.J. Diekema, M.A. Pfaller, R.A. Prince, K. Marchillo, and J. Ashbeck In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model Antimicrob Agents Chemother 52 2008 539 550 (Pubitemid 351170826)
25. A. Louie, M. Deziel, W. Liu, M.F. Drusano, T. Gumbo, and G.L. Drusano Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity Antimicrob Agents Chemother 49 2005 5058 5068 (Pubitemid 41778921)
26. M.A. Pfaller, D.J. Diekema, L. Boyken, S.A. Messer, S. Tendolkar, and R.J. Hollis Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis Antimicrob Agents Chemother 49 2005 4795 4797 (Pubitemid 41552623)
27. J.C. Bowman, P.S. Hicks, M.B. Kurtz, H. Rosen, D.M. Schmatz, and P.A. Liberator The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro Antimicrob Agents Chemother 46 2002 3001 3012 (Pubitemid 34898685)
28. R. Petraitiene, V. Petraitis, A.H. Groll, T. Sein, R.L. Schaufele, and A. Francesconi Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia Antimicrob Agents Chemother 46 2002 12 23 (Pubitemid 34031596)
29. N.P. Wiederhold, D.P. Kontoyiannis, J. Chi, R.A. Prince, V.H. Tam, and R.E. Lewis Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity J Infect Dis 190 2004 1464 1471 (Pubitemid 39332186)
30. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 200;47:3149-54.
31. D.A. Stevens, M. Espiritu, and R. Parmar Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations Antimicrob Agents Chemother 48 2004 3407 3411 (Pubitemid 39129338)
32. E.J. Ernst, M.E. Klepser, and M.A. Pfaller Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans Antimicrob Agents Chemother 44 2000 1108 1111
33. E.K. Manavathu, M.S. Ramesh, I. Baskaran, L.T. Ganesan, and P.H. Chandrasekar A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans J Antimicrob Chemother 53 2004 386 389 (Pubitemid 38239980)
34. Merck and co. Cancidas (caspofungin acetate for intravenous injection). Prescribing information (February 2005).
35. Astellas Pharma. Mycamine (micafungin sodium for injection). Prescribing information (June 2006).
36. Pfizer Inc. Eraxis (anidulafungin for injection). Prescribing information (March 2006).
37. J.A. Stone, E.M. Migoya, L. Hickey, G.A. Winchell, P. Deutsch, and K. Ghosh Potential for interactions between caspofungin and nelfinavir or rifampin Antimicrob Agents Chemother 48 2004 4306 4314 (Pubitemid 39434891)
38. M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, and J. Keims Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunters J Clin Pharmacol 45 2005 1018 1024 (Pubitemid 41192360)
39. M.F. Hebert, R.W. Townsend, S. Austin, G. Balan, D.K. Blough, and D. Buell Concomitant ciclosporin and micafungin pharmacokinetics in healthy volunters J Clin Pharmacol 45 2005 954 960 (Pubitemid 41060236)
40. J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, and I.E. Weston Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine J Clin Pharmacol 45 2005 227 233 (Pubitemid 40490447)
41. M. Stogniew, J. Dowell, D. Krause, and T.J. Henkel Population pharmacokinetics confirms absence of anidulafungin drug-drug interactions 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4 Prague 2004 Abstract 1035
42. J.A. Dowell, J. Scharanz, M. Stogniew, D. Krause, and T. Henkel Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. European Congress of Clinical Microbiology and Infectious Disease Prague 2004 Abstract 1036
43. P.L. Mc Cormack, and C.M. Perry Caspofungin: a review of its use in the treatment of fungal infections Drugs 65 2005 2049 2068 (Pubitemid 41327370)
44. J. Dowell, J. Schranz, J. Wilson, A. Baruch, and G. Foster Anidulafungina (ANID) pharmacokinetics are not affected by concomitant voriconazole (VORI) 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4 Prague 2004 Abstract 1034
45. J.A. Dowell, J. Schranz, A. Baruch, and G. Foster Safety and pharmacokinetics of coadministered voriconazol and anidulafungin J Clin Pharmacol 45 2005 1373 1382 (Pubitemid 41642440)
46. A. Philip, Z. Odabasi, J. Rodriguez, V.L. Paetznick, E. Chen, and J.H. Rex In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp Antimicrob Agents Chemother 49 2005 3572 3574 (Pubitemid 41060623)
47. J. Schranz, J. Dowell, D. Krause, and T. Henkel Anidulafungin and cyclosporine: safe coadministration without dosing adjustment 15th Congress of the International Society for Human and Animal Mycology May 25-29, USA 2003
48. J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, and B. Damle Lack of pharmacokinetic interaction between anidulafungin and tacrolimus J Clin Pharmacol 47 2007 305 314 (Pubitemid 46294710)
49. R. Herbrecht, D. Graham, M. Schuster, T. Henkel, D. Krause, J. Scharanz, et al. Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA) Program and abstracts of Tandem Bone Marrow Trasplantation Meeting (Orlando, FI) Arlington Heights, IL, American Society for Blood and Marrow Transplantation, 91 2004 Abstract 251
50. R. Hurren, S.L. Davis, and J.A. Vazquez What is the risk of disulfiram-like reaction during anidulafungin and metronidazole administration? 47th ICAAC. Chicago 2007 K-2158
51. D.S. Krause, A.E. Simjee, and C. Van Rensburg A randomized, double-blind trial of anidulafungin versus fluconazol for the treatment of esophageal candidiasis Clin Infect Dis 39 2004 770 775 (Pubitemid 39244288)
52. J. Schranz, D. Krause, and T. Henkel Lack of infusion related adverse events with anidulafungin 15th Congress of the International Society for Human and Animal Mycology May 25-29, TX, USA 2003 Abstract 399
53. D. Thye, B. Shepherd, R.J. White, I.E. Weston, and T. Henkel Anidulafungin: a Phase 1 Study to Identify the Maximum Tolerated Dose in Healthy Volunteers 41th Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19. Chicago 2001 Abstract 36
54. D.S. Krause, J. Reinhardt, J.A. Vazquez, A. Reboli, B.P. Goldstein, M. Wible Anidulafungin Invasive Candidiasis Study Group Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Antimicrob Agents Chemother 48 2004 2021 2024 (Pubitemid 38691592)
55. D. Krause, J. Schranz, and W. Birmingham Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs fluconazol (FLU) in patients with esophageal candidiasis (EC) 41th Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19. Chicago 2001 Abstract 136
56. J.A. Schranz, D. Krause, B.P. Golstein, and T. Henkel Efficacy of anidulafungin (ANID) for the treatment of candidemia 43th Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, Chicago 2003 Abstract 971
57. K.A. Marr, R. Hachem, G. Papanicolaou, J. Somani, J.M. Arduino, and C.J. Lipka Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A Transpl Infect Dis 6 2004 110 116 (Pubitemid 40013050)